desmond balakrishnan

HempFusion Wellness Inc. Announces 2021 AGM Voting Results

HempFusion Wellness Inc. ( TSX:CBD.U ) ( US:CBDHF ) ( FWB:8OO ) (" HempFusion " or the " Company "), a leading health and wellness consumer packaged goods Company, is pleased to announce the voting results from its Annual General Meeting of holders (" Shareholders ") of common shares (" Common   Shares ") the Company held Friday, May 14, 2021 in a virtual-only format (the " Meeting ").

All the matters put forward before Shareholders for consideration and approval as set out in the Company's management information circular dated April 7, 2021 (the " Circular ") were approved by the requisite majority of votes cast at the Meeting. In particular, Shareholders approved the election of all director nominees as follows:

Votes in Favour

Votes Withheld

% of Votes Cast in
Favour (rounded)

Jason Mitchell

21,035,729

4,869,944

81.20%

Ian Dequeiroz

21,031,598

4,874,075

81.19%

G. Scott Greenburg

21,036,498

4,869,175

81.20%

Nick Grafton

20,969,966

4,935,707

80.95%

Merrick Andlinger

25,901,338

4,335

99.98%

David Doherty

25,577,442

328,231

98.73%

Gordon Fox

25,835,206

70,467

99.73%

Desmond Balakrishnan

20,710,133

5,195,540

79.94%

Shareholders also approved the appointment of MNP LLP as auditor of the Company for the ensuing year.

The total number of Common Shares represented by Shareholders in person or by proxy at the Meeting was 26,247,492 Common Shares, representing 22.37% of the total issued and outstanding Common Shares. Detailed voting results are available under the Company's profile on SEDAR at www.sedar.com .

ABOUT HEMPFUSION

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion's diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion's wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion's CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .

Follow HempFusion on Twitter, Facebook and Instagram and Probulin on Twitter, Facebook and Instagram.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638

News Provided by Business Wire via QuoteMedia

The Conversation (0)

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types

- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona . The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m. Central Time, on Monday, November 18th, 2024, at the American Heart Association Scientific Sessions 2024. Dr. S. Allen Luis, Co-Director, Pericardial Diseases Clinic and Associate Professor of Medicine, Department of Cardiovascular Medicine at the Mayo Clinic, will present on behalf of the MAvERIC-Pilot investigators.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA IN SMALL CELL LUNG CANCER AT WCLC 2024

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC

DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday Sept. 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, and Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Appendix 4E and Preliminary Final Report - For the Year Ended 30 June 2024

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”) has released its Appendix 4E Preliminary Final Report.


Keep reading...Show less
Hydralyte

H1 FY24 Half Year Report and Appendix 4D: 29% Reduction in Net Cash Used in Operating Activities alongside Stable Revenue

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to provide the following update on the six-month period ended 30 June 2024 (the “half year” or “H1 FY2024”) and the Company’s Appendix 4D.

Keep reading...Show less

Latest Press Releases

Related News

×